1122
Slow acetylators, who comprise roughly 50% of the South African population, are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy.
 Slow acetylators: Subject; Slow acetylators: Subject.Disorder; clinical and biochemical features of phenytoin toxicity: Effect; phenytoin: Treatment; together with antituberculosis: Treatment; antituberculosis: Treatment.Drug; phenytoin: Treatment.Drug; phenytoin: Combination.Drug; antituberculosis: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 Slow acetylators: Subject; Slow acetylators: Subject.Disorder; clinical and biochemical features of phenytoin toxicity: Effect; phenytoin: Treatment; together with antituberculosis: Treatment; antituberculosis: Treatment.Drug; phenytoin: Treatment.Drug; phenytoin: Combination.Drug; antituberculosis: Combination.Drug